Vabysmo met the primary endpoint of noninferior visual acuity gains compared with aflibercept treatment at 24 weeks in patients with retinal vein occlusion in the phase 3 BALATON and COMINO studies, according to a Genentech press release.
Participants were randomly assigned 1:1 to receive six monthly injections of Vabysmo 6 mg (faricimab-svoa) or aflibercept 2 mg for 20 weeks for the treatment of macular edema due to branch and central retinal vein occlusion.
In BALATON, vision gains were 16.9 letters in those treated with Vabysmo compared with 17.5 letters in (Read more...)